

Bibliography

1. 189. Morgan, A. H. Jeffers, T. A. Petrie, J. C. Walker W. Drug advertising in medical journals. *British Journal of Clinical Pharmacology* 1976; 3:1057-1060.
2. A Govt plans incentives for Pharmaceutical industry. 06/01/2008 Available at http://www.khaleejtimes.com/displayarticlenew.asp?Xfile=data/business/2008/January/business_January126.xml§ion=business&col= (Accessed on 10/02/2008).
3. Abate, Marie A. Jackowitz, Arthur I. Shumway, James M. Information sources utilized by private practice and university physicians. *Drug Information Journal* 1989; 23:304-319.
4. AD/Rx: 1993 annual analysis. Kulpsville, Pennsylvania: Consultants in Pharmaceutical Media, Inc; 1993.
5. Ahmad, Syed Rizwanuddin. Bhutta, Zulfiqar Ahmed. A survey of pediatric prescribing and dispensing in Karachi. *Journal of the Pakistan Medical Association* 1990; 40:126-130.
6. Aldir, Rodolfo E. Jarjoura, David. Phinney, Melinda. Poordad, Fred. Gutierrez, Robert. Marnejon, Thomas. Greifenstein, Elaine. Lappin, Joan. Whittier, Frederick C. Practicing and resident physician's views on pharmaceutical companies. *Journal of Continuing Education in the Health Professions* 1996; 16:25-32.
7. Aldir, Rodolfo E. Jarjoura, David. Phinney, Melinda. Poordad, Fred. Gutierrez, Robert. Marnejon, Thomas. Greifenstein, Elaine. Lappin, Joan. Whittier, Frederick C. Practicing and resident physician's views on pharmaceutical companies. *Journal of Continuing Education in the Health Professions* 1996;16:25-32.
8. Alloza, José Luis. Lasagna, Louis. A comparison of drug product information in four national compendia. *Clinical Pharmacology and Therapeutics* 1983;33:269-277.
9. Al-Maskari, F. (2010) Life style diseases: An economic burden on the health services. *UN Chronicle*, 47 (2), 28 July, United Nations, http://www.un.org/wcm/content/site/chronicle/cache/bypass/lang/en/home/archive/issues2010/achieving_global_health/economic_burden_on_health_services?Ctnscroll_articlecontainer_list=1_0&ctnlistpagination_articleContainerList=true,accessed25september,2010.
10. Alperstein, Neil M. Peyrot, Mark. Consumer awareness of prescription drug advertising. *Journal of Advertising Research* 1993; 33:50-56.

11. Alperstein, Neil M. Peyrot, Mark. Consumer awareness of prescription drug advertising. *Journal of Advertising Research* 1993;33:50-56.
12. American Business Press, Advertising Research Foundation. *Product growth: how can it be achieved in an era of tighter resources?* New York: American Business Press; 1993. 116. Leisten, Volker. Schmieder, Wilfried. Wenzel, Jnrge. Proof of effectiveness: “pharmaads”. Arbeitsgemeinschaft LAMED; October 1993.
13. Amonkar, Mayur Mohan. Lively, Buford T. Pharmacists’ attitudes toward product specific television advertising of prescription drugs. *Journal of Pharmaceutical Marketing & Management* 1996; 11:3-20.
14. Amonkar, Mayur Mohan. Lively, Buford T. Pharmacists’ attitudes toward product specific television advertising of prescription drugs. *Journal of Pharmaceutical Marketing & Management* 1996;11:3-20.
15. Anastasio, Geraldine D. Little, John M. Pharmaceutical marketing: implications for medical residency training. *Pharmacotherapy* 1996;16:103-107.
16. Andaleeb, Syed Saad. Tallman, Robert F. Physician attitudes toward pharmaceutical sales representatives. *Health Care Marketing Review* 1995;20:68-76.
17. Anderson, Jennifer J. Felson, David T. Meenan, Robert F. Secular changes in published clinical trials of second-line agents in rheumatoid arthritis. *Arthritis and Rheumatism* 1991;34:1304-1309.
18. Applbaum, k. (2006, april 5). Pharmaceutical marketing and the invention of the medical consumer. *Plos medicine* , pp. 0445-0447.
19. Applbaum, k. (2006, april 5). Pharmaceutical marketing and the invention of the medical consumer. *Plos medicine* , pp. 0445-0447.
20. Arora, P. (2005) Healthcare biotechnology firms in India: Evolution, structure and growth. *Current Science* 89(3): 458–464. Artistic /pds 2003/pds 2003.html attitudes of psychiatry residents, interns and clerks. Canadian Medical Association Available from: http://www.wto.org/english/tratop_e/trips_e/who_background_e.pdf, accessed on December 20, 2009.
21. Assocham. (2006). White paper on indian pharma industry quest for global leadership. New delhi: cygnus.
22. Assocham. (2006). White paper on indian pharma industry quest for global leadership. New delhi: cygnus.

23. Atos. (2006). Trend & issues pharmaceutical industry. Sa: atos.
24. Atos. (2006). Trend & issues pharmaceutical industry. Sa: atos.
25. Avorn, Jerry. Chen, Milton. Hartley, Robert. Scientific versus commercial sources of influence on the prescribing behavior of physicians. *American Journal of Medicine* 1982;73:4-8.
26. Azimi, Nassir A. Welch, H. Gilbert. The effectiveness of cost-effectiveness analysis in containing costs. *Journal of General Internal Medicine* 1998;13:664-669.
27. Backer, Elisabeth L. Lebsack, Jason A. Van Tonder, R.J.N. Crabtree, Benjamin F. The value of pharmaceutical representative visits and medication samples in community based family practices. *Journal of Family Practice* 2000;49:811-816.
28. Banks, James W. III. Mainous, Arch G. III. Attitudes of medical school faculty toward gifts from the pharmaceutical industry. *Academic Medicine*
29. Bansinath, M. Sequeira, R. P. Shukla, V. K. Mathur, V. S. Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 1984; 22:279-283.
30. Bansinath, M. Sequeira, R. P. Shukla, V. K. Mathur, V. S. Brand versus generic prescribing: a perspective of the Indian cardiologists' viewpoint. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 1984;22:279-283.
31. Bardelay, Danielle. Bécel, Bernard. Visits from medical representatives: fine principles, poor practice. *Prescrire International* 1995;4:120-122.
32. Barnes, Charles J. Holcenberg, John S. Student reactions to pharmaceutical promotion practices. *Northwest Medicine* 1971;70:262-266.
33. Basara, Lisa Ruby. The impact of a direct-to-consumer prescription medication advertising campaign on new prescription volume. *Drug Information Journal* 1996;30:715- 729.
34. Bates, a. K. (2006). Online marketing and edetailing: in-depth report from an eyeforpharma conference. Conference review (pp. 298-300). Berlin: palgrave macmillan ltd.
35. Bates, a. K. (2006). Online marketing and edetailing: in-depth report from an eyeforpharma conference. Conference review (pp. 298-300). Berlin: palgrave macmillan ltd.

36. Bates, A., Bailey, E. And Rajyaguru, I. (2002) Navigating the detailing maze. *International Journal of Medical Marketing* 2 (3): 255–262.
37. Becker, Marshall H. Stolley, Paul D. Lasagna, Louis. Mcevilla, Joseph D. Sloane, Lois M. Differential education concerning therapeutics and resultant physician prescribing Patterns. *Journal of Medical Education* 1972;47:118-127.
38. Bell, Robert A. Kravitz, Richard L. Wilkes, Michael S. Direct-to-consumer prescription drug advertising and the public. *Journal of General Internal Medicine* 1999; 14:651-657.
39. Bell, Robert A. Kravitz, Richard L. Wilkes, Michael S. Direct-to-consumer prescription drug advertising and the public. *Journal of General Internal Medicine* 1999;14:651-657.
40. Bell, Robert A. Wilkes, Michael S. Kravitz, Richard L. Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses.
41. Benseman, John. The great paper waste: the use of unsolicited medical literature by general practitioners. *New Zealand Family Physician* 1985; 12:96-98.
42. Benseman, John. The great paper waste: the use of unsolicited medical literature by general practitioners. *New Zealand Family Physician* 1985;12:96-98.
43. Berings, D. Blondeel, L. Habraken, H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. *European Journal of Clinical Pharmacology* 1994;46:501-505.
44. Bero, Lisa A. Rennie, Drummond. Influences on the quality of published drug studies. *International Journal of Technology Assessment in Health Care* 1996;12:209-237.
45. Bertoldi AD, Barros AJ, Hallal PC Generic drugs in Brazil: known by many, used by few. *Cad Saude publica*. 2005; 21: 1808-15.
46. Bertoldi AD, Barros AJ, Hallal PC Generic drugs in Brazil: known by many, used by few. *Cad Saude publica*. 2005; 21: 1808-15.
47. Bhangale, v. (2008). Pharma marketing in india:opportunities, challenges and the way forward. *Journal of medical marketing* , 205-210.
48. Bhangale, v. (2008). Pharma marketing in india:opportunities, challenges and the way forward. *Journal of medical marketing* , 205-210.
49. Bhangale, V.(2008)Pharma marketing in India: Opportunities, challenges and the way forward. *Journal of Medical Marketing* 8(3): 205–210.

50. Bhat, V.N. (2005) Patent term extension strategies in the pharmaceutical industry. *Pharmaceuticals Policy and Law* 6:109–122.
51. Biga J, Taboulet F, Lapeyre-Mestre M, Duguet, A.M., Vincent, S., Montastruc, J. L. Prescribing drugs by international non-proprietary name: the perception of health and non-health professionals. *Therapie*.2005; 60: 401-7.
52. Biga J, Taboulet F, Lapeyre-Mestre M, Duguet, A.M., Vincent, S., Montastruc, J. L. Prescribing drugs by international non-proprietary name: the perception of health and non-health professionals. *Therapie*.2005; 60: 401-7.
53. Biotech News. (2008)National Biotechnology Development Strategy. III (3):22.
54. Birkett DJ. Generics Equal or not? *Australian Prescriber*. 2003; 26, 85-87.
55. Black, I. (2005) Pharmaceutical marketing strategy: Lessons from the medical literature. *Journal of Medical Marketing* 5(2): 119–125.
56. Blake, Robert L. Jr. Early, Elizabeth K. Patients' attitudes about gifts to physicians from pharmaceutical companies. *Journal of the American Board of Family Practice* 1995;8: 457-464.
57. Blake, Robert L. Jr. Early, Elizabeth K. Patients' attitudes about gifts to physicians from pharmaceutical companies. *Journal of the American Board of Family Practice* 1995;8:457-464.
58. Blumenthal, David. Campbell, Eric G. Anderson, Melissa S. Causino, Nancyanne. Louis, Karen Seashore. Withholding research results in academic life science: evidence from a national survey of faculty. *JAMA* 1997;277:1224-1228.
59. Blumenthal, David. Campbell, Eric G. Causino, Nancyanne Louis, Karen Seashore. Participation of life science faculty in research relationships with industry. *New England Journal of Medicine* 1996;335:1734-1739.
60. Blumenthal, David. Causino, Nancyanne. Campbell, Eric. Louis, Karen Seashore. Relationships between academic institutions and industry in the life sciences: an industry survey. *New England Journal of Medicine* 1996;334:368-373.
61. Blumenthal, David. Gluck, Michael. Louis, Karen Seashore. Stoto, Michael A. Wise, David. University-industry research relationships in biotechnology: implications for the university. *Science* 1986;232:1361-1366.

62. Boerkamp, E. J. C. Haaijer-Ruskmap, F. M. Reuyl, J. C. Versluis, A. The use of drug information sources by physicians: development of a data-generating methodology. *Social Science and Medicine* 1996; 42:379-388.
63. Boerkamp, E. J. C. Haaijer-Ruskmap, F. M. Reuyl, J. C. Versluis, A. The use of drug information sources by physicians: development of a data-generating methodology. *Social Science and Medicine* 1996;42:379-388.
64. Boulding, W., Staelin, R., Ehret, M. And Johnston, W.J. (2005), a customer relationship management roadmap: What is known, potential pit falls, and where to go. *Journal of Marketing* 69 (October):155–166.
65. Bower, Anthony D. Burkett, Gary L. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. *Journal of Family Practice* 1987;24:612-616.
66. Bowman, Marjorie A. Pearle, David L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. *Journal of Continuing Education* 1988;8:13-20.
67. Bowman, Marjorie A. The impact of drug company funding on the content of continuing medical education. *Mobius* 1986;6:66-69.
68. Brotzman, Gregory L. Mark, David H. Policies regulating the activities of pharmaceutical representatives in residency programs. *Journal of Family Practice* 1992;34:54-57.
69. Brotzman, Gregory L. Mark, David H. The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities. *Journal of General Internal Medicine* 1993;8:130-134.
70. Brower, A. (2006) ‘Generic’ biotech products: Are the flood gates open? At whose expense? *Biotechnology Healthcare*, (August) 22–23.
71. Bucci, Kathryn K. Frey, Keith A. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives. *Journal of Family Practice* 1992; 34:49-52.
72. Bucci, Kathryn K. Frey, Keith A. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives. *Journal of Family Practice* 1992;34:49-52.
73. Buckley, J. (2004) the need to develop responsible marketing practice in the pharmaceutical sector. *Problems and Perspectives in Management*, April, 4:92–103.

74. Buckley, j. (2004). The need to develop responsible marketing practice in the pharmaceutical sector. *Problems and perspectives in management* , 92-103.
75. Buckley, j. (2004). The need to develop responsible marketing practice in the pharmaceutical sector. *Problems and perspectives in management* , 92-103.
76. Campbell, Eric G. Louis, Karen Seashore. Blumenthal, David. Looking a gift horse in the mouth: corporate gifts supporting life sciences research. *JAMA* 1998;279:995-999.
77. Carandang, Edelisa D. Moulds, Robert F. W. Pharmaceutical advertisements in Australian medical publications - have they improved?. *Medical Journal of Australia* 1994;161:671-672.
78. Cardenas, Eduardo Zarate. Isenrich, Lucia Llosa. Prescribing habits of Peruvian physicians and factors influencing them. *Bulletin of PAHO* 1995;29:328-337.
79. Carroué, L. (2009) the heart of the American automobile has stopped beating *Le-Monde Diplomatique*. February.
80. Caudill, T. Shawn. Johnson, Mitzi S. Rich, Eugene C. Mckinney, W. Paul. Physicians, pharmaceutical sales representatives, and the cost of prescribing. *Archives of Family Medicine* 1996;5:201-206.
81. Caudron, J. (2007) Care organization in the United States: The consecration of ‘any private’, <http://www.legrandsoir.info>, February.
82. Center for Drug Evaluation and Research. 2004. Report to the Nation 2003. Rockville, MD: FDA Chandon, P. (2004) Innovative marketing strategies after patent expiry: The case of GSK’s antibiotic clamoxylin France. *International Journal of Medical Marketing* 4(1): 65–73.
83. Center for Drug Evaluation and Research. 2004. Report to the Nation 2003. Rockville, MD: FDA WHO Medicines Strategy Countries at the Core 2004-2007, http://whqlibdoc.who.int/hq/2004/WHO_EDM_2004.2.pdf, Accessed 25th November 2007.
84. Centre urged to lower prices of drugs. Http://www.dawn.com/2007/09/30/local_7.htm , Accessed 25th November 2007.
85. Chaganti, s. R. (2007). *Pharmaceutical marketing in india:concepts strategy cases*. Hyderabad: pharma book syndicate.

86. Chaganti, s. R. (2007). Pharmaceutical marketing in india: concepts strategy cases. Hyderabad: pharma book syndicate.
87. Chard, Jiri A. Tallon, Deborah. Dieppe, Paul A. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. *Annals of the Rheumatic Diseases* 2000;59:414-418.
88. Chaudhury, s. (2005). The wto and india's pharmaceutical industry. New delhi: oxford university press.
89. Chaudhury, s. (2005). The wto and india's pharmaceutical industry. New delhi: oxford university press.
90. Chew, Lisa D. O'Young, Theresa S. Hazlet, Thomas K. Bradley, Katharine A. Maynard, Charles. Lessler, Daniel S. A physician survey of the effect of drug sample availability on physicians' behavior. *Journal of General Internal Medicine* 2000;15:478-483.
91. Chirac, P. Pikon, A. Poinsignon, Y. Vitry, A. Drug marketing in French-speaking African countries. *Social Science and Medicine* 1993;36:1541-1543.
92. Cho, Mildred K. Bero, Lisa A. The quality of drug studies published in symposium proceedings. *Annals of Internal Medicine* 1996;124:485-489.
93. Choudhry, Niteesh K. Stelfox, Henry Thomas. Detsky, Allan S. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. *JAMA* 2002;287:612-617.
94. Chren, Mary-Margaret. Landefeld, C. Seth. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. *JAMA* 1994;271:684-689.
95. Christensen, Dale B. Wertheimer, Albert I. Sources of information and influence on new drug prescribing among physicians in an HMO. *Social Science and Medicine* 1979;13A:313-322.
96. Christoph burmann, j. M. (2010). Customer centricity as a key to success for pharma. *Journal of medical marketing* , 1-11.
97. Christoph burmann, j. M. (2010). Customer centricity as a key to success for pharma. *Journal of medical marketing* , 1-11.
98. Christopher, A.(2006) Block buster patent expirations bring a shift in business models. *Pharmacy Times*, October.

99. Cleary, John D. Impact of pharmaceutical sales representatives on physician antibiotic prescribing. *Journal of Pharmacy Technology* 1992;8:27-29.
100. Cockerill, Rhonda. Williams, Paul. Report on the 1989 survey of the dispensing practices Control of drug advertising in Canada. Ottawa: Drugs Directorate; October 25, 1994.
101. Cockerill, Rhonda. Williams, Paul. Report on the 1989 survey of the dispensing practices and attitudes toward prescription drugs of Ontario pharmacists. Toronto: Province of Ontario; 1990(?)
102. Cormack, M. A. Howells, E. Factors linked to the prescribing of benzodiazepines by general practice principals and trainees. *Family Practice* 1992;9:466-471.
103. Cravens, D.W. and Piercy, N.F. (2009) *Strategic Marketing*. New Delhi, India: Tata Mc Graw Hill. Cutrer, Christine M. Pleil, Andreas M. Potential outcomes associated with direct-to consumer
104. Curry, Lynn. Putnam, R. Wayne. Continuing medical education in Maritime Canada: the methods physicians use, would prefer and find most effective. *Canadian Medical Association Journal* 1981;124:563-566.
105. Cutrer, Christine M. Pleil, Andreas M. Potential outcomes associated with direct-to consumer advertising of prescription drugs: physicians' perspectives. *Journal of Pharmaceutical Marketing & Management* 1991;5: 3-19.
106. Dajda, Richard. Drug advertising and prescribing. *Journal of the Royal College of General Practitioners* 1978;28:538-541.
107. Dasta, Joseph F. Visconti, James A. Hawksworth, K. The adoption of clarithromycin by university-based physicians during its first year of commercial availability. *Journal of Pharmaceutical Marketing & Management* 1995;9:3-20.
108. Davidson, Richard A. Source of funding and outcome of clinical trials. *Journal of General Internal Medicine* 1986;1:155-158.
109. Davidson, T. And Davidson, E. (2004) Details drive success. *Marketing of Health Services*, Spring, 24(1): 20–25.
110. Day,P.(2009)Tinker, tailor, soldier, major– Professor Veronica Hope-Hailey discusses the changing role of job titles on Radio 4's‘ In Business’ program, http://www.bath.ac.uk/management/news_events/news/2004/28-9.html.

111. Deskmukh, N.(2006) VC funds for biotech gaining momentum in India. Bio Spectrum, July 2006.
112. Dhawan, a. (2015). 2015 health care outlook india. Gurgaon: deloitte.
113. Dhawan, a. (2015). 2015 health care outlook india. Gurgaon: deloitte.
114. Dickersin, Kay. Min, Yuan-I. Meinert, Curtis L. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374-378.
115. Dieperink, Michael. Drogemuller, Lisa. Industry-sponsored grand rounds and prescribing behavior. JAMA 2001;285:1443-1444.
116. Dieppe, Paul. Chard, Jiri. Tallon, Deborah. Egger, Matthias. Funding clinical research. Lancet 1999;353:1626.
117. Dikshit, R. K. Dikshit, N. Commercial source of drug information: comparison between the United Kingdom and India. BMJ 1994;309:990-991.
118. Directorate of Economics & Statistics (Government of National Capital Territory of Delhi). National Sample Survey 63rd Round (State sample). July 2006-June 2007. New Delhi: Government of NCT Delhi; 2008.
119. Directorate of Economics & Statistics. Government of National Capital Territory of Delhi). National Sample Survey 62nd Round (State sample), July 2005-June 2006. New Delhi: Government of NCT Delhi; 2007.
120. Dixit, n. (2008). A study of the role of government of india in helping indian pharma industry cope up with the challenges of product patent regime. European journal of economics, finance and administrative sciences , 47-56.
121. Dixit, n. (2008). A study of the role of government of india in helping indian pharma industry cope up with the challenges of product patent regime. European journal of economics, finance and administrative sciences , 47-56.
122. Djulbegovic, B. Bennett, C.L. Lyman, G.H. Violation of the uncertainty principle in conduct of randomized controlled trials (rcts) of erythropoietin (EPO).Blood 1999;94:399a Tallon, Deborah. Chard, Jiri. Dieppe, Paul. Relation between agendas of the research community and the research consumer. Lancet 2000;355:2037-2040.

123. Djulbegovic, Benjamin. Lacevic, Mensura. Cantor, Alan. Fields, Karen K. Bennett, Charles L. Adams, Jared R. Kuderer, Nicole M. Lyman, Gary H. The uncertainty principle and industry-sponsored research. *Lancet* 2000;356:635-638.
124. Doha Declaration on TRIPS and Public Health, signed at WTO Ministerial meeting in Doha, Qatar on 14 November 2001
125. Doha Declaration on TRIPS and Public Health, signed at WTO Ministerial meeting in Doha, Qatar on 14 November 2001
126. Dorman, Paul J. Counsell, Carl. Sandercock, Peter. Reports of randomized trials in acute stroke, 1955 to 1995: what proportions were commercially sponsored? *Stroke* 1999;30:1995-1998.
127. Drug Control Organization, Ministry of Health, Government of Pakistan (2005), <http://www.dcomoh.gov.pk/> Accessed 10th November 2007.
128. Drug Control Organization, Ministry of Health, Government of Pakistan (2005), <http://www.dcomoh.gov.pk/> Accessed 10th November 2007 Syed R (2007). Pharma exports to touch \$600m by 2010: exporters. June 2007. Available at http://www.dailytimes.com.pk/default.asp?Page=2007%5C06%5C30%5Cstory_30-6-2007_pg5_2. (Accessed on 09/02/08).
129. Drug promotion: What we know, what we have yet to learn 90 Cady, Paul S. Larson, Lon N. Brief summary and the believability of consumer prescription drug advertising. *Journal of Pharmaceutical Marketing & Management* 1989;3:65-72.
130. Drug promotion: What we know, what we have yet to learn 92 Wilkes, Michael S. Hoffman, Jerome R. An innovative approach to educating medical students about pharmaceutical promotion. *Academic Medicine* 2001;76:1271-1277.
131. Dubey, r. D. (2009). Pharmaceutical product differentiation: a strategy for strengthening product pipeline and life cycle management. *Journal of medical marketing* , 104-118.
132. Dubey, r. D. (2009). Pharmaceutical product differentiation: a strategy for strengthening product pipeline and life cycle management. *Journal of medical marketing* , 104-118.
133. Dunn, Earl. William, J. Ivan. Bryans, A.M. Davis, David. Delmore, Terry. Herron, Anna. Krauser, John. Scott, David J. Continuing medical education in Ontario: a primary care perspective. *Canadian Family Physician* 1982; 28:1327-1333.

134. Dunn, Earl. William, J. Ivan. Bryans, A.M. Davis, David. Delmore, Terry. Herron, Anna. Krauser, John. Scott, David J. Continuing medical education in Ontario: a primary care perspective. *Canadian Family Physician* 1982;28:1327-1333.
135. Easterbrook, Philippa J. Berlin, Jesse A. Gopalan, Ramana. Matthews, David R. Publication bias in clinical research. *Lancet* 1991;337:867-872.
136. Eaton, Gail. Parish, Peter. General practitioners' views of information about drugs. *Journal of the Royal College of General Practitioners* 1976; 26:64-68.
137. Eaton, Gail. Parish, Peter. General practitioners' views of information about drugs. *Journal of the Royal College of General Practitioners* 1976;26:64-68.
138. Eaton, Gail. Parish, Peter. Sources of drug information used by general practitioners *Journal of the Royal College of General Practitioners* 1976;26:58-64.
139. Economic survey of Pakistan, 2003– 2004. Islamabad: Government of Pakistan, Finance Division, Economic Advisers Wing;2004.
140. Economic survey of Pakistan, 2003– 2004. Islamabad: Government of Pakistan, Finance Division, Economic Advisers Wing;2004.
141. Eichner, Riva. Maronick, Thomas J. A review of direct-to-consumer (DTC) advertising and sales of prescription drugs: does DTC advertising increase sales and market share? *Journal of Pharmaceutical Marketing & Management* 2001;13:19-42.
142. Eleventh Five Year Plan 2007-2012, vol. II, Social sector. Planning Commission, Government of India. Delhi: Oxford University Press; 2008. P. 57-127.
143. Emmerich, g. I. (2008). Marketing strategy-the need for new promotional models. *Journal of medical marketing* , 23-30.
144. Emmerich, g. I. (2008). Marketing strategy-the need for new promotional models. *Journal of medical marketing* , 23-30.
145. Engle, Robert L. The impact of a single-advertiser publication on physicians' perceptions and expected prescribing behavior. *Journal of Pharmaceutical Marketing & Management* 1994;8:37-54.
146. Evans, Kenneth R. Beltramini, Richard F. Physician acquisition of prescription drug information. *Journal of Health Care Marketing* 1986;6:15-25.

147. Everett, Stephen E. Lay audience response to prescription drug advertising. *Journal of Advertising Research* 1991;31:43-49.
148. Ferguson, Robert P. Rhim, Eugene. Belizaire, Waindel. Egede, Leonard. Carter, Kennita. Lansdale, Thomas. Encounters with pharmaceutical sales representatives among practicing internists. *American Journal of Medicine* 1999;107:149-152.
149. Ferry, Margaret E. Lamy, Peter P. Becker, Lorne A. Physicians' knowledge of prescribing for the elderly: a study of primary care physicians in Pennsylvania. *Journal of the American Geriatric Society* 1985;33:616-622.
150. Ficci. (2005). Competitiveness of the indian pharmaceutical industry in the new product patent regime. New delhi: ficci.
151. Ficci. (2005). Competitiveness of the indian pharmaceutical industry in the new product patent regime. New delhi: ficci.
152. Fisherow, W. Benjamin. The shape of prescription drug advertising: a survey of promotional techniques and regulatory trends. *Food Drug Cosmetic Law Journal* 1987;42:213-236.
153. Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician's education lower the cost of prescription drugs? A prospective controlled trial. *Ann Intern Med* 1991; 115 : 116-21.
154. Freemantle, N. Anderson, I.M. Young, P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: meta-regression analysis. *British Journal of Psychiatry* 2000;177:292-302.
155. Frew,S.E.,Rezaie, R.,Sammut, S.M.,Ray,M., Daar, A.S.and singer, P.A.(2007) India's health biotech sector at a crossroads. *Nature Biotechnology* 25:403-417.
156. Friedberg, Mark. Saffran, Bernard. Stinson, Tammy J. Nelson, Wendy. Bennett, Charles L. Evaluation of conflict of interest in economic drugs used in oncology. *JAMA* 1999;282:1453-1457.
157. Friedman, M. And Gould, J.(2007) Physicians' attitudes toward direct-to consumer prescription drug marketing. *Journal of Medical Marketing* 7(1):33-44.
158. Gaither, Caroline A. Bagozzi, Richard P. Kirking, Duane M. Ascione, Frank J. Factors related to physicians' attitudes and beliefs toward drug information sources. *Drug Information Journal* 1994;28:817-827.

159. Gambrill, J. Bridges-Webb, C. Use of sources of therapeutic and prescribing Gewin, V.(2005) Making it in the biotech business. *Nature* 435:124–125.
160. Gambrill, J. Bridges-Webb, C. Use of sources of therapeutic and prescribing information by general practitioners. *Australian Family Physician* 1980;9:482-484.
161. Ganjree, k. A. (2011). *Pharmaceutical marketing-strategies and practices*. Ahmedabad: international book house p. Ltd.
162. Ganjree, k. A. (2011). *Pharmaceutical marketing-strategies and practices*. Ahmedabad: international book house p. Ltd.
163. Gibbons, Robert V. Landry, Frank J. Blouch, Denise L. Jones, David L. Williams, Frederick K. Lucey, Catherine R. Kroenke, Kurt. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. *Journal of General Internal Medicine* 1998;13:151-154.
164. Gibbons, Robert V. Landry, Frank J. Blouch, Denise L. Jones, David L. Williams, Frederick K. Lucey, Catherine R. Kroenke, Kurt. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. *Journal of General Internal Medicine* 1998;13:151-154.
165. Glick,J.L.(2007) Biotech business model thrives. *Genetic Engineering & Biotechnology News* 27(13):6–7.
166. Godwin SK,Varatharajan D. Drug price differentials across different retail market settings. *Health Administrator* 2006; 19 : 41-7.
167. Gönül, Füsün. F. Carter, Franklin. Petrova, Elina. Srinivasan, Kannan. Promotion of prescription drugs and its impact on physicians' choice behavior. *Journal of Marketing* 2001;65:79-90.
168. Gonul,F.F. ,Carter, F.,Petrova, E. And Srinivasan, K.(2001) Promotion of prescription drugs and its impact on physicians' choice behavior. *Journal of Marketing* 65(3):79–90.
169. Gonzales AG. The drugs don't work: access to medicines in the developing world. *ICFAI J Health care Law* 2007; 5 : 41-74.
170. Government of India. Draft National Pharmaceutical Policy 2006, Part A. Delhi. Available from: http://chemicals.nic.in/npp_circulation_latest.pdf, accessed on December 6, 2009.
171. Government of India. Drug Policy 1986. Delhi. Available from: <http://nppaindia.nic.in/Dp1986mod.htm>, accessed on December 6, 2009.

172. Government of India. National Health Policy (India) 2002. Delhi. Available from: [http://www.mohfw.nic.in/NRHM/ Documents/National Health policy_2002.pdf](http://www.mohfw.nic.in/NRHM/Documents/National Health policy_2002.pdf), accessed on December 6, 2009.
173. Government of National Capital Territory Delhi. Directorate of Economics & Statistics. Delhi statistical handbook. New Delhi: Government of India Press; 2006.
174. Government of National capital Territory of Delhi. Economic Survey of Delhi 2008- 09. Available from: <http://www.delhiplanning.nic.in/Economics%Survey/ES2008-09.html>, accessed on February 10, 2010.
175. Government of National Capital Territory of Delhi. Labour Department. Minimum monthly wage rates. Available from: [http://www.delhi.gov.in /wcm /connect /doit_labour/labour Home/ Minimum +Wages /Rates+at++a+glance](http://www.delhi.gov.in/wcm/connect/doit_labour/labour Home/ Minimum +Wages /Rates+at++a+glance), accessed on December 6, 2009.
176. Government wants sale of drugs under generic names, [http://www.dawn.com/2007/10/25/localgreene,W.\(2007\) The Emergence of India's Pharmaceutical Industry and Implications for the US Generic Drug Market. US International Trade Commission, Office of Economics Working Paper no.2007-05-A,pp.1-41](http://www.dawn.com/2007/10/25/localgreene,W.(2007) The Emergence of India's Pharmaceutical Industry and Implications for the US Generic Drug Market. US International Trade Commission, Office of Economics Working Paper no.2007-05-A,pp.1-41).
177. Government wants sale of drugs under generic names, <http://www.dawn.com/2007/10/25/local17.htm>, Accessed 25th November 2007.
178. Grace, c. (june 2004). The effect of changing intellectual property on pharmaceutical industry prospects in india and china. London: dfid health systems resource centre.
179. Grace, c. (june 2004). The effect of changing intellectual property on pharmaceutical industry prospects in india and china. London: dfid health systems resource centre.
180. Greenwell ,M.(2009) The last hope for hungry kid. Washington Post,30May.
181. Greenwood, Justin. Pharmaceutical representatives and the prescribing of drugs by familydoctors. Nottingham University; 1989 (unpublished).
182. Greenwood, Justin. Prescribing and salesmanship. HAI News 989:1-2, 11. Lexchin, Joel. Interactions between physicians and the pharmaceutical industry: what does the literature say? Canadian Medical Association Journal 1993;149:1401-1407.
183. Güldal, Dilek. Semin, Semih. The influence of drug companies' advertising programs on physicians. International Journal of Health Services 2000;30:585-595.

184. Güldal, Dilek. Semin, Semih. The influence of drug companies' advertising programs on physicians. *International Journal of Health Services* 2000;30:585-595.
185. Haayer, Flora. Rational prescribing and sources of information. *Social Science and Medicine* 1982;16:2017-2023.
186. Hartmann,L.(2008)The United States and health. The cost of U.S. health care system–The stands of health no.19.
187. Hassali MA., Kong DCM. Stewart, K. Utilisation of generic medicines in the Australian healthcare system. *Journal of Generic Medicines*. 2004; 2: 42-52.
188. Hassali MA., Kong DCM. Stewart, K. Utilisation of generic medicines in the Australian healthcare system. *Journal of Generic Medicines*. 2004; 2: 42-52.
189. Hatton, Randy C. Doering, Paul L. Frias, Jaime L. Physicians' sources of information about teratogenic effects of drugs. *Drug Information Journal* 1982;16:148-154.
190. Hawkins,D.(2006) Drug discovery and development in India: An up tapped seam of out sourcing opportunities. *Genetic Engineering & Biotechnology News* 26:3.
191. Hayes, T. M. Allery, L. A. Harding, K. G. Owen, P.A. Continuing education for general practice and the role of the pharmaceutical industry. *British Journal of General Practice* 1990;40:510-512.
192. Hayes, T. M. Allery, L. A. Harding, K. G. Owen, P.A. Continuing education for general practice and the role of the pharmaceutical industry. *British Journal of General Practice* 1990;40:510-512.
193. Hemminki, Elina. The effect of a doctor's personal characteristics and working circumstances on the prescribing of psychotropic drugs. *Medical Care* 1974;12:351-357.
194. Herring, j. (2010). Strategic partnering supplement. La: covance.
195. Herring, j. (2010). Strategic partnering supplement. La: covance.
196. Herxheimer, Andrew. Collier, Joe. Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. *BMJ* 1990;300:307-311.
197. Hibberd, Patricia L. Meadows, A. J. Use of drug information sources by hospital doctors. *Journal of Information Science* 1980;2:169-172.

198. Hodges, Brian. Interactions with the pharmaceutical industry: experiences and http://www.dailytimes.com.pk/default.asp?Page=2007%5C06%5C30%5Cstory_30-6-2007_pg5_2. (Accessed on 09/02/08).
199. Hodges, Brian. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. *Canadian Medical Association Journal* 1995;153:553-559.
200. Hoechst to discontinue Baralgin (dipyrone/pitofenone/fenpiverinium). *Malam International News* 1995;13:2.
201. Hopper, John A. Speece, Mark W. Musial, Joseph L. Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. *Journal of General Internal Medicine* 1997;12:639-642.
202. [Http://www.iht.com/articles/ap/2008/09/19/business/NA-US-genericdrugs-Buyout.php](http://www.iht.com/articles/ap/2008/09/19/business/NA-US-genericdrugs-Buyout.php).
203. Hull, F. M. Marshall, T. Sources of information about new drugs and attitudes towards drug prescribing: an international study of differences between primary care physicians. *Family Practice* 1987;4:123-128.
204. Hume, Anne L. Shaughnessy, Allen F. Sources of influence on the prescribing practices of residents in family medicine. *DICP, The Annals of Pharmacotherapy* 1991;25:102-103.
205. Hume, Anne L. Shaughnessy, Allen F. Sources of influence on the prescribing practices of residents in family medicine. *DICP, The Annals of Pharmacotherapy* 1991;25:102-103.
206. Hurd, Peter. The potential value of unfavorable information. *Medical Marketing & Media* 1980;15:42-44, 46.
207. Huston, Patricia. Moher, David. Redundancy, disaggregation, and the integrity of medical research. *Lancet* 1996;347:1024-1026.
208. IFPMA.(2010)IFPMA code of pharmaceutical marketing practices, [http://www.ifpma.org/Issues/III\(3\):14-15](http://www.ifpma.org/Issues/III(3):14-15).
209. IMS health, http://www.imshealth.com/web/channel /0,3147, 64639575_ 63872702 _ 76856130, 00 information by general practitioners. *Australian Family Physician* 1980; 9: 482-484.
210. Inman, William. Pearce, Gillian. Prescriber profile and post-marketing surveillance. *Lancet* 1993;342:658-661.

211. Ioannidis, John P.A. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. *JAMA* 1998;279:281-286.
212. Ivens,B.S.and Pardo,C.(2008)Key-account management in business markets: An empirical test of common assumptions. *Journal of Business & Industrial Marketing* 23(5):301–310.
213. Jamshed s, b. Z. (2009). Generic medicines as a way to improve access and affordability: a proposed framework for pakistan. *Journal of clinical and diagnostic research* , 1596-1600.
214. Jamshed s, b. Z. (2009). Generic medicines as a way to improve access and affordability: a proposed framework for pakistan. *Journal of clinical and diagnostic research* , 1596-1600.
215. Jadad, Alejandro R. Moher, Michael. Browman, George P. Booker, Lynda Sigouin, Christopher. Fuentes, Mario. Stevens, Robert. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. *BMJ* 2000;320:537-540.
216. Jagdale,S.(2008) Indian biotech’s global designs. *Express Pharma*. [Http://www.expresspharmaonline.com/20080215/bioasia2008special01.shtml](http://www.expresspharmaonline.com/20080215/bioasia2008special01.shtml),accessedseptember2008.
217. Jakobowicz PB, Rainhorn JD, Reich MR, editors. Indicators for monitoring national drug policies: a practical manual. World Health Organization; Geneva; 1994. WHO/DAP/94.12.
218. Jayakrishna,S.(2006)New age pharma marketing. *Marketing Mastermind*6 (7):37–43.
219. Jayaraman,K.S.(2004)Foreign VC funds get mixed reception in India, <http://www.nature.com/bioent/2004/040401/full/bioent806.html>,accessedseptember2008.
220. Jewesson, Peter. Herar, Suman. Activities of pharmaceutical industry representatives at a major teaching hospital. *Canadian Journal of Hospital Pharmacy* 1996;49:256-260.
221. Johansen, Helle Krogh. Gotzsche, Peter C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;282:1752-1759.
222. John, v. Y. (2009). Potential risk factors influencing the indian pharmaceutical industry-an exploratory study. *Indian journal of finance* , 31-36.
223. John, v. Y. (2009). Potential risk factors influencing the indian pharmaceutical industry-an exploratory study. *Indian journal of finance* , 31-36.
224. Jones, Miren I. Greenfield, Sheila M. Bradley, Colin P. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. *BMJ* 2001;323:378-384.

225. Joshi, h. N. (2003, january 6). Analysis of the indian pharmaceutical industry-with emphasis on opportunities in 2005. *Pharmaceutical technology* , pp. 74-94.
226. Joshi, h. N. (2003, january 6). Analysis of the indian pharmaceutical industry-with emphasis on opportunities in 2005. *Pharmaceutical technology* , pp. 74-94.
227. Kale, s. A. (november 2006). Experimentation with strategy in the indian pharmaceutical sector. Ikd working paper no.16 , 1-41.
228. Kale, s. A. (november 2006). Experimentation with strategy in the indian pharmaceutical sector. Ikd working paper no.16 , 1-41.
229. Kazakov, r. (2007). Between strategy and change:reformulating the medicines industry in an enlarged europe. *Journal of medical marketing* , 245-253.
230. Kazakov, r. (2007). Between strategy and change:reformulating the medicines industry in an enlarged europe. *Journal of medical marketing* , 245-253.
231. Keim, Samuel M. Sanders, Arthur B. Witzke, Donald B. Dyne, Pamela. Fulgniti, John W. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. *Annals of Emergency Medicine* 1993;22:1576-1581.
232. Keim, Samuel M. Sanders, Arthur B. Witzke, Donald B. Dyne, Pamela. Fulgniti, John W. Beliefs and practices of emergency medicine faculty and residents regarding professional interactions with the biomedical industry. *Annals of Emergency Medicine* 1993;22:1576-1581.
233. Kelcher, Sheila. Brownoff, Rene. Meadows, Lynn M. Structured approach to pharmaceutical representatives: family medicine residency program. *Canadian Family Physician* 1998;44:1053-1060.
234. Kemmeren, Jeanet M. Algra, Ale. Grobbee, Diederick E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. *BMJ* 2001;323:131-134.
235. Kersnik J. Peklar J. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. *J Clin Pharm Ther.* 2006; 31: 577-83.
236. Kersnik J. Peklar J. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. *J Clin Pharm Ther.* 2006; 31: 577-83.

237. Kevin buehler, a. F. (september 2008). Owing the right risks. Harvard business review , 102-110.
238. Kevin buehler, a. F. (september 2008). Owing the right risks. Harvard business review , 102-110.
239. KEYLENS.(2009)Der Königisttot–eslebeder König ,Customer Centricity–am Kunden ausgerichtete Unter nehmens steuerung. Düss eldorf, Germany: KEYLENS White Paper.
240. Kiani A, Qadeer A, Mirza Z, Khanum A, Tisocki K, Mustafa T Prices, availability and affordability of Medicines in Pakistan. Report of The Network for Consumer Protection, www.haiweb.org/medicineprices/surveys /200407PK/survey_report.pdf Accessed 25th November 2007.
241. Kiani A, Qadeer A, Mirza Z, Khanum A, Tisocki K, Mustafa T Prices, availability and affordability of Medicinesin Pakistan. Report of The Network forconsumer Protection, www.haiweb.org/medicineprices/surveys /200407PK/survey_report.pdf Accessed 25th November 2007.
242. King DR & Kanavos P. Encouraging the Use of Generic Medicines: Implications for Transition Economies. CMJ.2002; 43: 462-69.
243. King DR & Kanavos P. Encouraging the Use of Generic Medicines: Implications for Transition Economies. CMJ.2002; 43: 462-69.
244. Knox, K.S. Adams, J.R. Djulbegovic, B. Stinson, T.J. Tomori, C. Bennett, C.L. Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Annals of Oncology 2000;11:1591-1595. Kjaergard, Lise Lotte. Nikolova, Dimitrinka. Gluud, Christian. Randomized clinical trials in Hepatology: predictors of quality. Hepatology 1999;30:1134-1138.
245. Konde,V.(2008)Biotechnology in India: Public– private partnerships. Journal of Commercial Biotechnology 14:43–55.
246. Kotwani, a. (2010). Will generic drug stores improve access to essential medicines for the poor in india? Journal of public health policy , 178-184.
247. Kotwani, a. (2010). Will generic drug stores improve access to essential medicines for the poor in india? Journal of public health policy , 178-184.
248. Kpmg. (2006). The indian pharmaceutical industry:collaboration for growth. Swiss: kpmg.
249. Kpmg. (2006). The indian pharmaceutical industry:collaboration for growth. Swiss: kpmg.

250. Kresse,G.B.(2009) Bio-similar–Science, status, and strategic perspective. *European Journal of Pharmaceutics and Biopharmaceutics*,(in press).
251. Krinsky, Sheldon. Ennis, James G. Weissman, Robert. Academic-corporate ties in biotechnology: a quantitative study. *Science, Technology, & Human Values* 1991;16:275-287.
252. Krupka, Lawrence R. Vener, Arthur M. Prescription drug advertising: trends and implications. *Social Science and Medicine* 1985;20:191-197.
253. Kumar,A.(2007) Indian biotech bazaar: A SWOT analysis. *Biotechnology Journal* 2:543–545.
254. Kunin, Calvin M. Clinical investigators and the pharmaceutical industry. *Annals of Internal Medicine* 1978;89:842-845.
255. La Puma, John. Stocking, Carol B. Rhoades, William D. Darling, Cheryl M. Financial ties as part of informed consent to post-marketing research: attitudes of American doctors and patients. *BMJ* 1995; 310:1660-1663.
256. La Puma, John. Stocking, Carol B. Rhoades, William D. Darling, Cheryl M. Financial ties as part of informed consent to postmarketing research: attitudes of American doctors and patients. *BMJ* 1995;310:1660-1663.
257. Lagarce L, Lusson-Brisset C, Bruhat C, Diquet, B., Lainé-Cessac, P. How practitioners view generic drugs: an opinion study from general practitioners in Maine-et-Loire (France). *Therapie*. 2005; 60: 67-74
258. Lagarce L, Lusson-Brisset C, Bruhat C, Diquet, B., Lainé-Cessac, P. How practitioners view generic drugs: an opinion study from general practitioners in Maine-et-Loire (France). *Therapie*. 2005; 60: 67-74
259. Lal, A. Moharana, A. K. Chandra, P. Ray, A. Critical evaluation of references in drug advertisements: an Indian experience. *Journal of the Association of Physicians of India* 1996;44:778-779.
260. Larson, Lon N. Smith, Mickey C. An analysis of the effects of “fair balance” in prescription drug advertising. *Medical Marketing & Media* 1978;13:26-27, 31.
261. Larson, Lon N. Smith, Mickey C. Sharpe, Thomas R. Hy, Ronn. Garner, Dewey D. Government regulation and the believability of prescription drug advertising: an application of attribution theory and test of symbolic impact. *Drug Intelligence and Clinical Pharmacy* 1977;11:338-343.

262. Lefkowitz, David III. Rap sheet on reps: the doctor will see you now. *Pharmaceutical Executive* 1988;6:38-42
263. Lexchin, Joel. Enforcement of codes governing pharmaceutical promotion: what happens when companies breach advertising guidelines? *Canadian Medical Association Journal* 1997;156:351-356.
264. Lexchin, Joel. Holbrook, Anne. Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. *Canadian Medical Association Journal* 1994;151:47-54.
265. Lichstein, Peter R. Turner, Robert C. O'Brien, Kevin. Impact of pharmaceutical company representatives on internal medicine residency programs: a survey of residency program directors. *Archives of Internal Medicine* 1992;152:1009-1013.
266. Lichstein, Peter R. Turner, Robert C. O'Brien, Kevin. Impact of pharmaceutical company representatives on internal medicine residency programs: a survey of residency program directors. *Archives of Internal Medicine* 1992;152:1009-1013.
267. Liebeskind, David S. Kidwell, Chelsea S. Saver, Jeffrey L. Empiric evidence of publication bias affecting acute stroke clinical trials. *Stroke* 1999;30:268.
268. Linn, Lawrence S. Davis, Milton S. Physicians' orientation toward the legitimacy of drug use and their preferred source of new drug information. *Social Science and Medicine* 1972;6:199-203. Andaleeb, Syed Saad. Tallman, Robert F. Physician attitudes toward pharmaceutical sales representatives. *Health Care Marketing Review* 1995;20:68-76.
269. Linn, Lawrence S. Davis, Milton S. Physicians' orientation toward the legitimacy of drug use and their preferred source of new drug information. *Social Science and Medicine* 1972;6:199-203.
270. Lion, John R. Regan, Bruce L. Taylor, Ronald J. Kutzer, Dennis J. Psychiatrists' opinions of psychotropic drug advertisements. *Social Science & Medicine* 1979;13A:123-125.
271. Lion, John R. Regan, Bruce L. Taylor, Ronald J. Kutzer, Dennis J. Psychiatrists' opinions of psychotropic drug advertisements. *Social Science & Medicine* 1979;13A:123-125.
272. Lipsky, Martin S. Taylor, Christine A. The opinions and experiences of family physicians regarding direct-to-consumer advertising. *Journal of Family Practice* 1997;45:495-499.
273. Lipsky, Martin S. Taylor, Christine A. The opinions and experiences of family physicians regarding direct-to-consumer advertising. *Journal of Family Practice* 1997;45:495-499.

274. Lipton, Charles. Consumer advertising and pharmaceuticals: a happy marriage? *Journal of Pharmaceutical Marketing & Management* 1986;1:23-28.
275. Lipton, Charles. Consumer advertising and pharmaceuticals: a happy marriage? *Journal of Pharmaceutical Marketing & Management* 1986;1:23-28.
276. List of Pharmaceuticals, Retailers and whole sellers in Delhi, India [document on the internet]. Available from: [http:// www.indiacom.com/yellowpages/pharmaceuticals-retailers-and-wholesellers/Delhi Pharmaceuticals-retailers and wholesellers in Delhi, India](http://www.indiacom.com/yellowpages/pharmaceuticals-retailers-and-wholesellers/Delhi-Pharmaceuticals-retailers-and-wholesellers-in-Delhi-India), accessed on March 6, 2006.
277. Lo, Bernard. Wolf, Leslie E. Berkeley, Abiona. Conflict-of-interest policies for investigators in clinical trials. *New England Journal of Medicine* 2000;343:1616-1620.
278. Lucas, J.M. (2007) U.S. health care system: Reserve prognosis without intervention. *Economic outlook*.
279. Lurie, Nicole. Rich, Eugene C. Simpson, Deborah E. Meyer, Jeff. Schiedermayer, David L. Goodman, Jesse L. McKinney, W. Paul. Pharmaceutical representatives in academic medical centers: interaction with faculty and house staff. *Journal of General Internal Medicine* 1990;5:240-243.
280. Mack, j. (2009). The empowered patient. *Pharma marketing news* (pp. 2-7). Newtown: virsci corporation.
281. Mack, j. (2009). The empowered patient. *Pharma marketing news* (pp. 2-7). Newtown: virsci corporation.
282. Mackenzie, j. M. (2000). Strategic market segmentation: an opportunity to integrate medical and marketing activities. *International journal of medical marketing* , 40-52.
283. Mackenzie, j. M. (2000). Strategic market segmentation: an opportunity to integrate medical and marketing activities. *International journal of medical marketing* , 40-52.
284. Mackowiak, Elaine D. O'Connor, Thomas W. Geller, Hayley. Nguyen, Jessica. Wilkes, Wanda. A survey of pharmacists' and pharmacy students' attitudes toward OTC advertising. *Journal of Pharmaceutical Marketing & Management* 1997;12:33-49.
285. Mackowiak, Elaine D. O'Connor, Thomas W. Geller, Hayley. Nguyen, Jessica. Wilkes, Wanda. A survey of pharmacists' and pharmacy students' attitudes toward OTC advertising. *Journal of Pharmaceutical Marketing & Management* 1997;12:33-49.

286. Mackowiak, John I. Gagnon, Jean Paul. Effects of promotion on pharmaceutical demand. *Social Science and Medicine* 1985;20:1191-1197.
287. Maddox, Lynda M. Katsanis, Lea Prevel. Direct-to-consumer advertising of prescription drugs in Canada: its potential effect on patient-physician interaction. *Journal of Pharmaceutical Marketing & Management* 1997;12:1-21.
288. Maddox, Lynda M. Katsanis, Lea Prevel. Direct-to-consumer advertising of prescription drugs in Canada: its potential effect on patient-physician interaction. *Journal of Pharmaceutical Marketing & Management* 1997;12:1-21.
289. Madhavan, S. Amonkar, M.M. Elliott, D. Burke, K. Gore, P. The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians. *Journal of Clinical Pharmacy and Therapeutics* 1997;22:207-215.
290. Madhavan, S. Amonkar, M.M. Elliott, D. Burke, K. Gore, P. The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians. *Journal of Clinical Pharmacy and Therapeutics* 1997;22:207-215.
291. Magazine Publishers of America. *Magazines: a healthy diagnosis. Return on investment for DTC pharmaceutical advertising. A study measuring the effectiveness of allergy advertising by PERZ/HCI.* New York: Magazine Publishers of America;1999.
292. Magazine Publishers of America. *Magazines: a healthy diagnosis. Return on investment for DTC pharmaceutical advertising. A study measuring the effectiveness of allergy advertising by PERZ/HCI.* New York: Magazine Publishers of America;1999.
293. Mahood, S. Zagozeski, C. Bradel, T. Lawrence, K. Pharmaceutical policies in Canadian family medicine training: survey of residency programs. *Canadian Family Physician* 1997;43:1947-1951.
294. Mainous, Arch G. III. Hueston, William J. Rich, Eugene C. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. *Archives of Family Medicine* 1995;4:335-339.
295. Mainous, Arch G. III. Hueston, William J. Rich, Eugene C. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. *Archives of Family Medicine* 1995;4:335-339.
296. Maiti,R. And Raghavendra,M.(2007) *clinicaltrialsinindia.pharmacologicalresearch*56:1–10.

297. Makinen M, Waters H, Rauch M, Almagambetova N, Bitran R, Gilson L, et al. Inequalities in health care use and expenditures: empirical data from eight developing countries and countries in transition. *Bull World Health Organ* 2000; 78 : 55-65.
298. Malhotra ,S., Kondal, A., Shafiq, N.,Sidhu,S .and Pandhi,P.(2005) Pharmaceutical company representatives' perception of factors influencing prescription writing. *Journal of Pharmaceutical Marketing &Management*16(4):97–106.
299. Mandelkern, Marshal. Manufacturer support and outcome. *Journal of Clinical Psychiatry* 1999;60:122.
300. Manning, Phil R. Denson, Teri A. How internists learned about cimetidine. *Annals of Internal Medicine* 1980;92:690-692.
301. Mansfield, Peter R. Classifying improvements to drug marketing and justifications for claims of efficacy. *International Journal of Risk & Safety in Medicine* 1991;2:171-184.
302. Mapes, Roy. Aspects of British general practitioners' prescribing. *Medical Care* 1977;15:371-381.
303. Massie, B. M. Rothenberg, D. Impact of pharmaceutical industry funding of clinical research: results of a survey of antianginal trials. *Circulation* 1984;70:II-390.
304. Matalia, Ned. Journal advertising works! Three studies say so! *Medical Marketing & Media* 1994;29:12-14, 16, 18-20.
305. McCormick, Brendan B. Tomlinson, George. Brill-Edwards, Patrick. Detsky, Allan S. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. *JAMA* 2001;286:1994- 1999.
306. Mccrary, S. Anderson, Cheryl B. Jakovljevic, Jelena. Khan, Tonya. Mccullough, Laurence B. Wray, Nelda P. Brody, Baruch A. A national survey of policies on disclosure of conflicts of interest in biomedical research. *New England Journal of Medicine* 2000;343:1621-1626.
307. Mccue, Jack D. Hansen, Charles J. Gal, Peter. Physicians' opinions of the accuracy,
308. Mccue, Jack D. Hansen, Charles J. Gal, Peter. Physicians' opinions of the accuracy, accessibility, and frequency of use of ten sources of new drug information. *Southern Medical Journal* 1986;79:441-443.
309. Mcdonald, M., Millman, T. And Rogers, B.(1997) Key account management: Theory, practice and challenges. *Journal of Marketing Management* 13(8):737–757.

310. McDonald, M. (2000) Key account management— A domain review. *Marketing Review* 1(1):15.
311. McKinney, W. Paul. Schiedermayer, David L. Lurie, Nicole. Simpson, Deborah E. Goodman, Jesse L. Rich, Eugene C. Attitudes of internal medicine faculty and residents toward professional interactions with pharmaceutical sales representatives. *JAMA* 1990;264:1693-1697.
312. McKinney, W. Paul. Schiedermayer, David L. Lurie, Nicole. Simpson, Deborah E. Goodman, Jesse L. Rich, Eugene C. Attitudes of internal medicine faculty and residents toward professional interactions with pharmaceutical sales representatives. *JAMA* 1990;264:1693-1697.
313. Mcmillan, J. H. Information about medicines. *New Zealand Medical Journal* 1982;95:674-675.
314. Mcmillan, J. H. Information about medicines. *New Zealand Medical Journal* 1982;95:674-675.
315. Meffert, H., Burmann, C. And Kirchgeorg, M. (2008) *Marketing. Grundlagen markt orientierter Unternehmensführung*, 10th edn. Wiesbaden, Germany: Gablerverlag.
316. Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low and middle income countries. *Bull World Health Organ* 2007; 85 : 279-88.
317. Miller, Lucinda G. Blum, Alan. Physician awareness of prescription drug costs: a missing element of drug advertising and promotion. *Journal of Family Practice* 1993;36:33-36.
318. Mintzes, Barbara. An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume II: literature review. Direct-to-consumer advertising of prescription drugs: what do we know thus far about its effects on health and health care services? Vancouver: Centre for Health Services and Policy Research; August 2001.
319. Mintzes, Barbara. Barer, Morris L. Kravitz, Richard L. Kazanjian, Armin Te. Bassett, Ken. Lexchin, Joel. Evans, Robert G. Pan, Richard. Marion, Stephen A. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. *BMJ* 2002;324:278-279.
320. Mintzes, Barbara. Kazanjian. Bassett, Ken. Lexchin, Joel. An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume IV: pills, persuasion and public health policies. Report of an expert survey on

direct-to-consumer advertising of prescription drugs in Canada, the United States and New Zealand. Vancouver: Centre for Health Services & Policy Research; June 2001.

321. Mintzes, Barbara. Kazanjian. Bassett, Ken. Lexchin, Joel. An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume IV:pills, persuasion and public health policies. Report of an expert survey on direct-to-consumer advertising of prescription drugs in Canada, the United States and New Zealand. Vancouver: Centre for Health Services & Policy Research; June 2001.
322. Monaghan MJ, Monaghan MS. Do market components account for higher US prescription prices. *Ann Pharmacother* 1996; 30 : 1489-94.
323. Morelli, Daniel. Koenigsberg, Marlon Russell. Sample medication dispensing in a residency practice. *Journal of Family Practice* 1992;34:42-48.
324. Morris, Louis A. Brinberg, David. Klimberg, Ronald. Millstein, Lloyd. Rivera, Carole. Consumer attitudes about advertisements for medicinal drugs. *Social Science & Medicine* 1986;22:629-636.
325. Morris, Louis A. Mazis, Michael B. Brinberg, David. Risk disclosures in televised prescription drug advertising to consumers. *Journal of Public Policy & Marketing* 1989;8:64-80.
326. Morris, Louis A. Millstein, Lloyd G. Drug advertising to consumers: effects of formats for magazine and television advertisements. *Food Drug Cosmetic Law Journal* 1984;39:497-503.
327. Moser, Robert H. The continuing search: FDA drug information survey. *JAMA* 1974;229:1336-1338.
328. Mossinghoff ,G.J. (1999) Overview of the Hatch-Waxman Act and its impact on the drug development process. *Food and Drug Law Journal* 54(2):187–194.
329. Moulds, R. F. W. Bochner, F. Wing, I. M. H. Drug advertising. *Medical Journal of Australia* 1986;145:178-179.
330. Moynihan, Ray. Bero, Lisa. Ross-Degnan, Dennis. Henry, David. Lee, Kirby. Watkins, Judy. Mah, Connie. Soumerai, Stephen B. Coverage by the news media of the benefits and risks of medications. *New England Journal of Medicine* 2000;342:1645-1650.
331. Moza,M.K.(2005) Collaborations to improve biotechindustryinindia.currentscience88:6.

332. Munos,B. (2006) Outlook: Can open source R&D reinvigorate drug research? *Nature Reviews Drug Discovery* 5:723–729.
333. Murray,S.A.,Grant,E.,Grant,A .and Kendall, M. (2003) Dying from cancer in developed and developing countries: Lessons from two qualitative interview studies of patients and the carers. *British Medical Journal* 326(368):1–5.
334. Murray-Lyon, N. Communication in medicine: a study of how family doctors obtain information on recent advances in the treatment of rheumatic diseases. *Medical Education* 1997;11:95-102.
335. N.udupa, m. D. (2007, may 10). Ethics in pharmaceutical products promotion. *Current science* , p. 1195.
336. N.udupa, m. D. (2007, may 10). Ethics in pharmaceutical products promotion. *Current science* , p. 1195.
337. Najman, Jakob M. Siskind, Victor. Bain, Christopher. Prescription drug advertising: medical journal practices under different types of control. *Medical Journal of Australia* 1979;1:420-424.
338. Narayanan,S., Desi raju, R. And Chintagunta, P.K. (2004) Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. *Journal of Marketing* 68(4):90–105.
339. Natesh, A. *Biotech News Newsletter*. Department of Biotechnology, Government of India, 2(6), December 2007.
340. National Sample Survey Organization (NSSO). Ministry of Statistics and Programme Implementation (Government of India). Household consumer expenditure in India NSS, 63rd Round, July 2006-June 2007. Report No. 527 (63/1.0/1). New Delhi: NSSO Government of India; 2008.
341. Obaid R, Obaid A, Saify Z S, Kamil N,Khan M H, Ahmed T, Ahmed S W.Pharmacokinetic differences of some generic tablet Gliclazide 80 mg on Pakistani population. *Pak J Pharm Sci.*2004; 17: 55-64. *Of Business & Industrial Marketing* 23(5):323–331.
342. Obaid R, Obaid A, Saify Z S, Kamil N,Khan M H, Ahmed T, Ahmed S W.Pharmacokinetic differences of some generic tablet Gliclazide 80 mg on Pakistani population. *Pak J Pharm Sci.*2004; 17: 55-64.

343. Office of Inspector General. Prescription drug advertisements in medical journals. Washington, DC: Department of Health and Human Services; 1992(?).
344. Oppenheim, Gene L. Erickson, Steven H. Ashworth, Clark. The family physician's knowledge of the cost of prescribed drugs. *Journal of Family Practice* 1981;12:1027-1030.
345. Organ, D.W. (1988) organizational citizenship behavior: the good soldier syndrome. Lexington, MA: Lexington Books.
346. Orlowski, James P. Wateska, Leon. The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. *Chest* 1992;102:270-273
347. Osifo, Nosakhare Guy. Overpromotion of drugs in international product package inserts. *Tropical Doctor* 1983;13:5-8.
348. Osiobe, Stephen A. Physicians' and pharmacists' drug information sources in Nigeria. *Drug Information Journal* 1988;22:553-563.
349. Osiobe, Stephen A. Sources of information for biomedical decision-making. *Methods of Information in Medicine* 1985;24:225-229.
350. Pakistan Demographic Survey 2003, Accessed <http://www.statpak.gov.pk/depts/fbs/st>
351. Pakistan Demographic Survey 2003, Accessed <http://www.statpak.gov.pk/depts/fbs/st> http://www.imshealth.com/web/channel/0,3147,64639575_63872702_76856130,00.html Accessed 10th November 2007.
352. Pakistan factsheet. [Http://www.dfid.gov.uk/countries/asia/pakistan.asp](http://www.dfid.gov.uk/countries/asia/pakistan.asp). Accessed 10th November
353. Pakistan factsheet. [Http://www.dfid.gov.uk/countries/asia/pakistan.asp](http://www.dfid.gov.uk/countries/asia/pakistan.asp). Accessed 10th November 2007.
354. Palmisano, Paul. Edelstein, Joan. Teaching drug promotion abuses to health profession students. *Journal of Medical Education* 1980;55:453-455.
355. Palmisano, Paul. Edelstein, Joan. Teaching drug promotion abuses to health profession students. *Journal of Medical Education* 1980;55:453-455.
356. Parboosingh, John. Lockyer, Jocelyn. McDougall, Gerald. Chugh, Urmil. How physicians make changes in their clinical practice: a study of physicians' perception of factors that

- facilitate this process. *Annals of the Royal College of Physicians and Surgeons of Canada* 1984;17:429-435.
357. Peacock, Susan. Two surveys of pharmaceutical promotion and advertising. Wellington, NZ: Public Health Association of New Zealand; September 1990.
 358. Peay, Marilyn Y. Peay, Edmund R. Differences among practitioners in patterns of Peet, N.P. (2005) *biotechnologyinindia.drugdiscoverytoday:biotechfocus10(17):1137–1139*.
 359. Peay, Marilyn Y. Peay, Edmund R. Differences among practitioners in patterns of preference for information sources in the adoption of new drugs. *Social Science and Medicine* 1984;18:1019-1025.
 360. Peay, Marilyn Y. Peay, Edmund R. Innovation in high risk drug therapy. *Social Science and Medicine* 1994;39:39-52.
 361. Peay, Marilyn Y. Peay, Edmund R. Patterns of preference for information sources in the adoption of new drugs by specialists. *Social Science and Medicine* 1990;31:467-476.
 362. Peay, Marilyn Y. Peay, Edmund R. The role of commercial sources in the adoption of a new drug. *Social Science and Medicine* 1988;26:1183-1189.
 363. Perlitz, u. (2008). *India's pharmaceutical industry on course of globalization*. Frankfurt: deutsche bank.
 364. Perlitz, u. (2008). *India's pharmaceutical industry on course of globalization*. Frankfurt: deutsche bank.
 365. Perri, Matthew. Dickson, W. Michael. Direct to consumer prescription drug advertising: consumer attitudes and physician reaction. *Journal of Pharmaceutical Marketing & Management* 1987;2:3-25.
 366. Petroschius, Susan M. Titus, Philip A. Hatch, Kathryn J. Physician attitudes toward pharmaceutical advertising. *Journal of Advertising Research* 1995;35:41-51.
 367. Petroschius, Susan M. Titus, Philip A. Hatch, Kathryn J. Physician attitudes toward pharmaceutical advertising. *Journal of Advertising Research* 1995; 35: 41-51.
 368. Philip kotler, h. K. (2010). *Marketing 3.0*. New delhi: wiley.
 369. Philip kotler, h. K. (2010). *Marketing 3.0*. New delhi: wiley.
 370. Pines, r. B. (2007). Customer-driven positioning: the next generation approach to pharmaceutical product positioning. *Journal of medical marketing* , 71-76.

371. Pines, r. B. (2007). Customer-driven positioning: the next generation approach to pharmaceutical product positioning. *Journal of medical marketing* , 71-76.
372. Pisani, e. (2012). Ifpma code of practice. Geneva: international federation of pharmaceutical manufacturers & association.
373. Pisani, e. (2012). Ifpma code of practice. Geneva: international federation of pharmaceutical manufacturers & association.
374. Pitt, Leyland. Nel, Deon. Pharmaceutical promotion tools-their relative importance. *European Journal of Marketing* 1988;22:7-14.
375. Pitt, Leyland. Nel, Deon. Pharmaceutical promotion tools-their relative importance. *European Journal of Marketing* 1988;22:7-14.
376. Podsak off, P. M., Mackenzie, S.B., Paine, J.B .and Bachrach ,B.G. (2000) Organizational citizen ship behaviors: A critical review of the theoretical and empirical literature and suggestions for future research. *Journal of Management* 26(3):513–563.
377. Poirier, Therese I. Giannetti, Vincent. Giudici, Raymond A. Pharmacists' and physicians' attitudes toward phamaceutical marketing practices. *American Journal of Hospital Pharmacy* 1994;51:378-381.
378. Poirier, Therese I. Giannetti, Vincent. Giudici, Raymond A. Pharmacists' and physicians' attitudes toward phamaceutical marketing practices. *American Journal of Hospital Pharmacy* 1994;51:378-381.
379. Pollock, a. (2011). Transforming the critique of big pharma. *The london school of economics and political science* , 1-13.
380. Pollock, a. (2011). Transforming the critique of big pharma. *The london school of economics and political science* , 1-13.
381. Porter, r. (2000). *Cambridge illustrated history-medicine*. Bangalore: panther publisher pvt ltd.
382. *Prevention Magazine*. International survey on wellness and consumer reaction to DTC advertising of prescription drugs. Vol.1. US report with international perspectives. Rodale Press, 2000/2001.
383. Pricewaterhousecoopers. (2009). *Pharma 2020: challenging business models which path will you take?* Uk: pwc.

384. Priolkar, s. (2009, january 05). Can india be pharmaceutical superpower in 2020? Pharma times , pp. 5-14.
385. Quraeshi ZA, Luqmani M, Malhotra N.Brands or generics: the dilemma of pharmaceutical marketing in a developing country. J Health Care Mark.1983; 3: 27-37.
386. Quraeshi ZA, Luqmani M, Malhotra N.Brands or generics: the dilemma of pharmaceutical marketing in a developing country. J Health Care Mark.1983; 3: 27-37.
387. Raim,L.(2009)whyobamahastomakeconcessionsonitshealthreform– L’Expansion.Com,August.
388. Rao KS, Nundy M, Dua AS. Delivery of health services in the private sector. In: Lal PG, Byword editorial consultants, editors. National Commission on Macroeconomics and Health. Financing and delivery of health care services in India. New Delhi: Ministry of Health & Family Welfare, Government of India; 2005. P. 89-104.ROY et al: COSTS & AFFORDABILITY OF MEDICINES IN INDIA 835
389. Reeder, Mike. Dougherty, James. White, Lynn J. Pharmaceutical representatives and emergency medicine residents: a national survey. Annals of Emergency Medicine 1993;22:1593-1596.
390. Reeder, Mike. Dougherty, James. White, Lynn J. Pharmaceutical representatives and emergency medicine residents: a national survey. Annals of Emergency Medicine 1993;22:1593-1596.
391. Reserve Bank of India. Handbook of Statistics on Indian Economy. Available from: www.rbi.org.in/scripts/annualpublications.aspx?Head=Handbook%20of%20Statistics%20on%20Indian%20Economy, accessed on July 25, 2011.
392. Rochon, Paula A. Gurwitz, Jerry H. Simms, Robert W. Fortin, Paul R. Felson, David T. Minaker, Kenneth L. Chalmers, Thomas C. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Archives of Internal Medicine 1994;154:157-163.
393. Rockwell, Tom. The Lifetime experience with prescription drug advertising exposed to consumers. Journal of Pharmaceutical Marketing & Management 1986;1:13-18.
394. Rockwell, Tom. The Lifetime experience with prescription drug advertising exposed to consumers. Journal of Pharmaceutical Marketing & Management 1986;1:13-18.
395. Roth, Martin S. Patterns in direct-to-consumer prescription drug print advertising and their public policy implications. Journal of Public Policy & Marketing 1996;15:63-75.

396. Rothermich, Elizabeth A. Pathak, Dev S. Smeenk, David A. Health-related quality-of life claims in prescription drug advertisements. *American Journal of Health-Systems Pharmacy* 1996;53:1565-1569.
397. Rothman and, H.and Kraft, A.(2005) Downstream and into deep biology: Evolving business models in 'toptier' genomics companies. *Journal of Commercial Biotechnology* 12(2):86-98.
398. Roughead, Elizabeth E. Gilbert, Andrew L. Harvey, Ken J. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? *International Journal of Health Services* 1998;28:269-279.
399. Roughead, Elizabeth Ellen. The pharmaceutical representative and medical practitioner encounter: implications for quality use of medicines. Bundoora, Australia: La Trobe University; August 1995.
400. Roy V, Rewari. Ambiguous drug pricing. A physician's dilemma. *Indian J Pharmacol* 1998; 30 : 404-7.
401. Rust,R.T.,Zeithaml,V.A and Lemon, K.N.(2004)Customer centered brand management. *Harvard Business Review* 82(9):110-118.
402. Rylko- Bauer, B .and Farmer, P.(2002)Managed care or managed inequality? A call for critiques of Sakhivel S. Access to essential drugs and medicines. In:Lal PG, Byword editorial consultants, editors. *National Commission on Macroeconomics and Health. Financing and delivery of health care services in India*. New Delhi: Ministry of Health & Family Welfare, Government of India; 2005. P. 185-210.
403. Sacristan, José A. Bolaños, Elena, Hernández, Jess. Soto, Javier. Galende, . Publication bias in health economic studies. *Pharmacoeconomics* 1997;11:289-291.
404. Sakhivel S. How effective is India's Drug Price control regime? Available from: <http://www.hsph.harvard.edu/research/takemi/files/RP256.pdf>, accessed on February 14, 2010.
405. Sales representatives: a damning report by Prescrire reps monitoring network. *Prescrire International* 1999;8:86-89.
406. Sandberg, Warren S. Carlos, Ruth. Sandberg, Elisabeth H. Roizen, Michael F. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products. *Academic Medicine* 1997;72:16-918.

407. Sansgiry, Shubhada. Sharp, William T. Sansgiry, Sujit S. Consumer understanding and interpretation of printed over-the-counter drug advertisements. *Journal of Pharmaceutical Marketing & Management* 1999;13:15-26.
408. Santell, John P. Sirdwell, Stephen W. Scheckelhoff, Douglas J. Perception of the role of medical-service representatives in hospitals. *American Journal of Hospital Pharmacy* 1990;47:1354-1359.
409. Sauviat,C.(2004)Health system in crisis Although privatized! *Chronicle International IRES* November 2004. Saxena,K. And jain,S. (2006) Paradigm shift in the marketing of drugs. *Scour*1(1):39–53.
410. Saxena, s. J. (2010). Lifestyle and general medicines: a study of promotional-mix strategies in india. *Journal of medical marketing* , 1-8.
411. Schellekens,H. And Ryff,J.C.(2002) ‘Biogenerics’: The off-patent biotech products. *Trends in Pharmacological Sciences* 23(3):119–121.
412. Schommer, Jon C. Doucette, William R. Mehta, Bella H. Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug. *Clinical Therapeutics* 1998;20:617-632.
413. Sergeant, Myles D. Hodgetts, P. Geoffrey. Godwin, Marshall. Walker, David M. C. Mchenry, Patty. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. *Canadian Medical Association Journal* 1996;155:1243-1248.
414. Sergeant, Myles D. Hodgetts, P. Geoffrey. Godwin, Marshall. Walker, David M. C. Mchenry, Patty. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. *Canadian Medical Association Journal* 1996;155:1243-1248.
415. Shah,D.,Rust,R.T.,Parasuraman,A.,Staelin,R.and Day,G.S.(2006) The path to customer centricity. *Journal of Service Research* 9 (November):113–124.
416. Shahani, r. (2006, july 10). Wanted, a pragmatic policy. *The hindu survey of indian industry* , p. 221.
417. Shannon,J.R.(1996)The new promotion smix: A proposed paradigm, process, and application. *Journal of Marketing- Theory and Practice* 4(1):56–69.
418. Shapiro,E.C.(1995)*fadsurfingintheboardroom,1stedn*.Reading,MA:Addison-Wesley.

419. Sharma S, Sethi GR, Sachdev GK, Gupta U, Gulati RK, editors. Standard treatment guidelines. A manual for medical therapeutics, 2nd ed. New Delhi: BPL Publications Pvt. Ltd.; 2005.
420. Shaughnessy, Allen F. Slawson, David C. Bennett, Joshua H. Teaching information mastery: evaluating information provided by pharmaceutical representatives. *Family Medicine* 1995;27:581-585.
421. Shearer, Stephen W. Gagnon, Jean Paul. Eckel, Fred M. Community, hospital and clinical pharmacists and drug information centers as physician drug information sources. *American Journal of Hospital Pharmacy* 1978;35:909-914.
422. Shearer, Stephen W. Gagnon, Jean Paul. Eckel, Fred M. Community, hospital and clinical pharmacists and drug information centers as physician drug information sources. *American Journal of Hospital Pharmacy* 1978;35:909-914.
423. Sigworth, Stephen K. Nettleman, Mary D. Cohen, Gail M. Pharmaceutical branding of resident physicians. *JAMA* 2001;286:1024-1025.
424. Sigworth, Stephen K. Nettleman, Mary D. Cohen, Gail M. Pharmaceutical branding of resident physicians. *JAMA* 2001;286:1024-1025.
425. Silverman, Milton. Lee, Philip R. Lydecker, Mia. Drug promotion: the Third World revisited. *International Journal of Health Services* 1986;16:659-667
426. Silverman, Milton. Lee, Philip R. Lydecker, Mia. Prescriptions for death: the drugging of the Third World. Berkeley:University of California Press;1982.
427. Silverman, Milton. Lee, Philip R. Lydecker, Mia. The drugging of the Third World. *International Journal of Health Services* 1982;12:585-596.
428. Silverman, Milton. Lydecker, Mia. Lee, Philip R. Bad medicine: the prescription drug industry in the Third World. Stanford: Stanford University Press; 1992
429. Silverman, Milton. The epidemiology of drug promotion. *International Journal of Health Services* 1977;7:157-166.
430. Smith, b. (2007). Excellence in medical marketing: origins, definition and precursors. *Journal of medical marketing* , 25-32.
431. Smith, b. D. (2009). Myth, reality and requirements in pharmaceutical key account management. *Journal of medical marketing* , 89-95.

432. Smith, m. (2004). Principles of pharmaceutical marketing. New delhi: cbs publishers & distributors.
433. Spingarn, Roger W. Berlin, Jesse A. Strom, Brian L. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? *Academic Medicine* 1996;71:86-88.
434. Stelfox, Henry Thomas. Chua, Grace. O'Rourke, Keith. Detsky, Allan S. Conflict of interest in the debate over calcium-channel antagonists. *New England Journal of Medicine* 1998;338:101-106.
435. Stern, Jerome M. Simes, R. John. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. *BMJ* 1997;315:640-645.
436. Stern, Robert S. Drug promotion for an unlabeled indication; the case of topical tretinoin. *New England Journal of Medicine* 1994;331: 1348-1349.
437. Stinson, E. Ray. Mueller, Dorothy A. Survey of health professionals' information habits and needs: conducted through personal interviews. *JAMA* 1980;243:140-143.
438. Stolley, Paul D. Becker, Marshall H. Lasagna, Louis. Mcevilla, Joseph D. Sloane, Lois M. The relationship between physician's characteristics and prescribing appropriateness. *Medical Care* 1972;10:17-28.
439. Strang, David. Gagnon, Micheline. Molloy, William. Bédard, Michel. Darzins, Peteris. Etchells, Edward. Davidson, Warren. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. *Annals of the Royal College of Physicians and Surgeons of Canada* 1996;29:474-478.
440. Strang, David. Gagnon, Micheline. Molloy, William. Bédard, Michel. Darzins, Peteris. Etchells, Edward. Davidson, Warren. National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives. *Annals of the Royal College of Physicians and Surgeons of Canada* 1996;29:474-478.
441. Stremersch,S .and vandyck,W. (2009) Marketing of the life sciences: A new framework and research agenda for an ascent field. *Journal of Marketing* 73(4):4–30.
442. Strickland-Hodge, B. Jepson, M. H. Identification and characterization of early and late prescribers in general practice. *Journal of the Royal Society of Medicine* 1982;75:341-345.
443. Strickland-Hodge, B. Jepson, M. H. Usage of information sources by general practitioners. *Journal of the Royal Society of Medicine* 1980;73:857-862.

444. Stross, Jeffrey K. Information sources and clinical decisions. *Journal of General Internal Medicine* 1987;2:155-159.
445. Suresh, C. G. Greene D. Coupe, M. O. Use of adenosine and effectiveness of pharmaceutical marketing. *Lancet* 1993;341:1539.
446. Suresh,N. And Rao,S. (2008) Contract research and manufacturing services: On the roll .*Biotech News Suryanarayan,S. (2008) Biopharma in India: Strides of precision. Biotech News III (3):7–8.*
447. Suryawati, Sri. Santoso, Budiono. Drug advertisements: a critical lesson for Indonesian students. *Essential Drugs Monitor* 1997;23.
448. Syed R (2007). Pharma exports to touch \$600m by 2010: exporters. June 2007. Available at Taneja,G. And Arora,U.(2007) Sales force management: A comparative analysis of major and upcoming pharmaceutical companies in India. *The IUP Journal of Marketing Management*, May: 69–77. Http://www.iupindia.in/507/IJMM_slesforce57.asp,accessed23june,2010.
449. Taylor, A. Violations of the international code of marketing of breast milk substitutes: prevalence in four countries. *BMJ* 1999;316:1117-1122.
450. Taylor, Ross J. Bond, Christine M. Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice. *British Journal of General Practice* 1991;41:244-248.
451. Tempest B. India: A global strategic asset for developed world market businesses. *Journal of Generic Medicines* 2006; 4: 37 – 42
452. Tempest B. India: A global strategic asset for developed world market businesses. *Journal of Generic Medicines* 2006; 4: 37 – 42
453. The World Medicines Situation (2004). World Health Organization, WHO/EDM/PAR/2004.5
454. The World Medicines Situation (2004). World Health Organization, WHO/EDM/PAR/2004.5 Birkett DJ. Generics Equal or not? *Australian Prescriber*. 2003; 26, 85-87.
455. This month . . . The results of malam’s questionnaire to our subscribers. *Malam Australian News* 1996;4:1-5.

456. Thomas, Joseph III. National survey of hospital policies on pharmaceutical sales representatives' activities. *American Journal of Hospital Pharmacy* 1987;44:1334-1340
457. Thomas, Joseph III. National survey of recent changes in hospital policies on pharmaceutical sales representatives' activities. *American Journal of Hospital Pharmacy* 1989;46:565-569.
458. Thomson, A. N. Craig, B. J. Barham, P. M. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. *British Journal of General Practice* 1994;44: 220-223.
459. Thomson, A. N. Craig, B. J. Barham, P. M. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. *British Journal of General Practice* 1994;44: 220-223.
460. Tomson, G. Angunawela, I. Patients, doctors and their drugs: a study at four levels of health care in an area of Sri Lanka. *European Journal of Clinical Pharmacology* 1990;39:463- 467.
461. Tomson, Göran. Weerasuriya, Kris. 'Codes' and practice: information in drug advertisements—an example from Sri Lanka. *Social Science and Medicine* 1990;31:737-741.
462. Tong, Kevin L. Lien, Chia-Yen. Do pharmaceutical representative misuse their drug samples? *Canadian Family Physician* 1995;41:1363-1366.
463. Tramer, Martin R. Reynolds, D. John M. Moore, R. Andrew. Mcquay, Henry J. Impact of covert duplicate publication on meta-analysis: a case study. *BMJ* 1997;315:635- 640.
464. Tucker, Gregory K. Smith, Mickey C. Direct-to-consumer advertising: effects of different formats of warning information disclosure on cognitive reactions of adults. *Journal of Pharmaceutical Marketing & Management* 1987;2:27-41.
465. US Congress, Office of Technology Assessment. Drug labeling in developing countries. Washington, DC: US Government Printing Office; February 1993.
466. Vandenbroucke, Jan P. Helmerhorst, Frans M. Rosendaal, Frits R. Competing interests and controversy about third generation oral contraceptives. *BMJ* 2000;320:381- 382.
467. Vincent aurentz, b. K. (2011). Revitalizing porfolio decision-making at merck serono s.a.-geneva. *Journal of commercial biotechnology* , 24-36.

468. Vinson, Daniel C. Mccandless, Bridget. Hosokawa, Michael C. Medical students' attitudes toward pharmaceutical marketing: possibilities for change. *Family Medicine* 1993;25:31-33.
469. Vo-Kyung, Song. Ok Kim, Jai. Investigation of the violations of pharmaceutical regulations in advertisements of children's medicines. Manila:1988.
470. Wade, V. A. Mansfield, P. R. Mcdonald, P. J. Drug companies' evidence to justify advertising. *Lancet* 1989;2:1261-1264.
471. Wahlbeck, Kristian. Adams, Clive. Sponsored drug trials show more-favourable outcomes. *BMJ* 1999;318:465.
472. Waller, P. C. Wood, S. M. Langman, M. J. S. Breckenridge, A. M. Rawlins, M. D. Review of company postmarketing surveillance studies. *BMJ* 1992;304:1470-1472.
473. Walton, Harold. A case for medical journal advertising. *Medical Marketing & Media* 1978;13:37-43.
474. Walton, Harold. Ad recognition and prescribing by physicians. *Journal of Advertising Research* 1980;20:39-48.
475. WBSITE/EXTERNAL/COUNTRIES/SOUTHASIAEXT/ INDIAEXTN10,, content PK141137 ~ page pi PK:141127~the sitepk12, accessed on July 30, 2011.
476. Webster,J.andwind,Y.(1972)A general model for understanding organizational buying behavior. *Journal of Marketing* 36(2):12–19.
477. Weilbaker,D.C.andweeks,W.A.(1997)Theevolutionofnationalaccountmanagement:Aliteratureperspective.*journalofpersonalselling&salesmanagement*17(4):49–59.
478. Westfall, John M. McCabe, Jennifer. Nicholas, Richard A. Personal use of drug samples by physicians and office staff. *JAMA* 1997;278:141-143.
479. Whelan, Ann Marie. Nagpal, Seema. Burge, Fred. Drug information resources in a family medicine residency training program. *Canadian Pharmaceutical Journal* 1994;127:39, 41-43, 46.
480. Whelan, Ann Marie. Nagpal, Seema. Burge, Fred. Drug information resources in a family medicine residency training program. *Canadian Pharmaceutical Journal* 1994;127:39, 41-43, 46.
481. WHO Globalization, Trade and Health, <http://www.who.int/trade/glossary/stor>

482. WHO Globalization, Trade and Health,<http://www.who.int/trade/glossary/story034/en/index.html>, Accessed 10th November 2007.
483. WHO Medicines Strategy Countries at the Core 2004-2007, <http://whqlibdoc.who.int/hq/2004/WHO>
484. Wilkes, Michael S. Bell, Robert A. Kravitz, Richard L. Direct-to-consumer prescription drug advertising: trends, impact, and implications. *Health Affairs* 2000;19:110-128.
485. Wilkes, Michael S. Doblin, Bruce H. Shapiro, Martin F. Pharmaceutical advertisements in leading medical journals: experts' assessments. *Annals of Internal Medicine* 1992;116:912-919.
486. Wilkes, Michael S. Kravitz, Richard L. Policies, practices, and attitudes of North American medical journal editors. *Journal of General Internal Medicine* 1995;10:443-450.
487. Williams, A. Paul. Cockerill, Rhonda. Report on the 1989 survey of the prescribing experiences and attitudes toward prescription drugs of Ontario physicians. Toronto: Government of Ontario; 1990(?).
488. Williams, James R. Hensel, Paul J. Changes in physicians' sources of pharmaceutical information: a review and analysis. *Journal of Health Care Marketing* 1991;11:46-60.
489. Williams, Paul A. Cockerill, Rhonda. Lowy, Frederick H. The physician as prescriber: relations between knowledge about prescription drugs, encounters with patients and the pharmaceutical industry, and prescription volume. *Health and Canadian Society* 1995;3;135- 166.
490. Williamson, P. M. How general practitioners assess risks in using new drugs. *Journal of the Royal College of General Practitioners* 1975;25:383-386.
491. Wittink,D.R. (2002) Analysis of ROI for Pharmaceutical Promotions. Paper presented at the Association of Medical Publications; 18 September, <http://www.vioworks.com/clients/amp>,accessed4may,2009.
492. World Bank. New Gobal poverty estimates - what it means for India. Available from: www.worldbank.org.in/
493. World Health Organization and Health Action International. Price availability and affordability. An international comparison of chronic disease medicines. Background report prepared for the WHO Planning Meeting on the Global initiative for treatment of chronic diseases. Cairo (Egypt)

494. World Health Organization. How to develop and implement a national drug policy WHO Policy perspectives on medicine, No.6. Geneva: WHO; 2002.
495. World Health Organization. The world medicines situation. Geneva. 2004. WHO/EDM/PAR/2004.5.
496. World Health Organization. World Health Statistics 2009. Geneva. Available from: http://www.who.int/entity/whosis/whostat/EN_WHS09_Full.pdf, accessed on December 6, 2009.
497. World Health Organization/ World Trade Organization 2001. More equitable pricing for essential drugs: What do we mean and what are the issues? Hosbjor (Norway): Background paper for differential pricing and financing of essential drugs.
498. [Www.dfidhealthrc.org/meta/documents/17%20april%20documents/Country%20 Profile-Pakistan.doc](http://www.dfidhealthrc.org/meta/documents/17%20april%20documents/Country%20Profile-Pakistan.doc) (Accessed on 10/20/2008)
499. [Www.dfidhealthrc.org/meta/documents/17%20april%20documents/Country%20 Profile-Pakistan.doc](http://www.dfidhealthrc.org/meta/documents/17%20april%20documents/Country%20 Profile-Pakistan.doc) (Accessed on 10/20/2008)
500. Zachry, Woodie M. III. Shepherd, Marvin D. Hinich, Melvin J. Wilson, James P. Brown, Carolyn M. Lawson, Kenneth A. Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. *American Journal of Health-System Pharmacy* 2002;59:42-49.
501. Ziegler, Michael G. Lew, Pauline. Singer, Brian C. The accuracy of drug information from pharmaceutical sales representatives. *JAMA* 1995;273:1296-1298
502. Zupancic ,D.(2008)Towards an integrated framework of key account management .*Journal* Zupancic,D. And Millner,M.(2008) International key account management in manufacturing companies: An exploratory approach of situate differentiation. *Journal of Business -to- Business Marketing* 15(4):455–475.